Pharmaceutical composition for resisting colitis-related colon cancer and application thereof

A composition and technology for colon cancer, applied in the field of medicine, can solve the problems of low efficiency of chemotherapy, low efficacy of 5-FU, multidrug resistance of tumors, etc., and achieve inhibition of development, significant anti-cancer effect, and reduction of dysplasia and tumors. the effect of

Active Publication Date: 2019-07-26
HAINAN MEDICAL COLLEGE
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Fluorouracil (5-FU) is one of the commonly used chemotherapeutic drugs. The drug has a clear mechanism of action and is cheap, but its chemotherapeutic efficiency is low, and the ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for resisting colitis-related colon cancer and application thereof
  • Pharmaceutical composition for resisting colitis-related colon cancer and application thereof
  • Pharmaceutical composition for resisting colitis-related colon cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-8

[0043] A pharmaceutical composition for resisting colitis-associated colon cancer, wherein the weights of the 5-FU and Polygonum fructus compositions are shown in Table 1, respectively.

Embodiment 1-9

[0044] Table 1 embodiment 1-9 drug composition

[0045] serial number 5-FU(g) Maple Polygonum Composition (g) The weight ratio of the maple and saffron Example 1 1 9.375 1:1 Example 2 1 18.75 2:1 Example 3 1 37.5 3:1 Example 4 1 75 4:1 Example 5 1 150 5:1 Example 6 1 300 1.5:1 Example 7 1 600 3.5:1 Example 8 1 750 2.5:1 Example 9 1 1125 2:1 Example 10 1 1406.25 2:1

[0046] Example 9 and Example 10 correspond to 5-FU 25mg / kg+FLZHW28.125g / kg and 5-FU20mg / kg+FLZHW28.125g / kg respectively

[0047] The preparation method of the pharmaceutical composition described in embodiment 1-10, comprises the following steps:

[0048] (1) Take maple syringa and Polygonum saponica, mix them, add water and decoct twice, the first time is 1.5 hours, and the second time is 1 hour, combine the decoctions, filter, and dry the extract to obtain the Polygonum japonica extract;

[0049] (2) Take the for...

Embodiment 11

[0052] A medicinal composition for resisting colitis-associated colon cancer, comprising: 10 g of Auranthus japonica and 10 g of Polygonum sp.

[0053] Its preparation method comprises the following steps:

[0054] Separately take Fructus Fructus and Polygonum sp., mix them, add water to decoct, and dry the extract to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicine, and in particular, relates to a pharmaceutical composition for resisting colitis-related colon cancer and an application thereof. The pharmaceutical composition comprises the following components: a daphniphyllum calycinum-herba polygoni salicifolii composition and fluorouracil (5-FU); the weight ratio of the daphniphyllum calycinum-herba polygoni salicifolii composition to fluorouracil is (9.375-1406.25):(0-1); and the daphniphyllum calycinum-herba polygoni salicifolii composition is composed of daphniphyllum calycinum and herba polygoni salicifolii. The composition combines the daphniphyllum calycinum-herba polygoni salicifolii composition with the 5-FU, and achieves synergism of the therapeutic effect of the 5-FU on colorectal cancer. Thecombination therapy can become a more effective method for treating colorectal cancer.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a pharmaceutical composition for resisting colitis-associated colon cancer and its application. Background technique [0002] Cancer, also known as malignant tumor, is a general term for many related diseases. When a cell in the body mutates, it divides continuously without the body's control, eventually forming cancer. Cancer has become one of the diseases that seriously endanger human health. At present, the treatment methods for cancer mainly include surgery, chemotherapy, radiotherapy, immunotherapy, interventional therapy, traditional Chinese medicine therapy and so on. [0003] Fluorouracil (5-FU) is one of the commonly used chemotherapeutic drugs. The drug has a clear mechanism of action and is cheap, but its chemotherapeutic efficiency is low, and the tumor inhibition rate is only 20%-30%, and it is easy to cause tumor multidrug Therefore, it is urgent to develop a new and saf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/704A61P35/00A61K31/513
CPCA61K31/513A61K36/185A61K36/704A61K2236/331A61P35/00A61K2300/00
Inventor 黄凌
Owner HAINAN MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap